Baird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.Skorney ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' MaintainedMarch 2, 2015 8:43 AM Cowen Downgrades Sarepta Therapeutic (SRPT) to Market PerformFebruary 27, 2015 9:15 AM Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015February 26, 2015 7:07 AM